stockrow
Friday 6 November 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
39.96
0.39
−0.97%
Follow MDLN
Alert me
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
50.68 | 50.68 | 50.68 |
Altman Z-Score |
— | — | 2.25 |
P/S ratio |
0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | 2.84 |
P/FCF ratio |
0.00 | 0.00 | 10.06 |
Beneish M-Score |
— | — | (2.38) |
P/Operating CF |
0.00 | 0.00 | 19.51 |
P/B ratio |
0.00 | 0.00 | 1.76 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
3.76 | 3.76 | 10.16 |
EV/FCF |
4.66 | 4.66 | 13.20 |
Quick Ratio |
— | 1.40 | 2.20 |
Current Ratio |
— | 3.39 | 4.29 |
Net Debt/EBITDA |
0.00 | 5.08 | 3.24 |
Debt/Assets |
0.00% | 45.84% | 32.64% |
Debt/Equity |
0.00 | 1.02 | 0.65 |
Asset Turnover |
0.00 | 1.42 | 0.76 |
Operating CF/Net income |
7.20 | 1.47 | 1.50 |
Capex/Depreciation |
(0.25) | (0.33) | (0.42) |
Interest Coverage |
1.28 | 2.48 | 2.72 |
| 0.00% | 0.00% | 6.54% | |
| 0.00% | 6.67% | 3.11% | |
ROIC |
0.00% | 4.13% | 4.62% |
Return on Tangible Assets |
0.00% | 11.51% | 8.94% |
Average Days of Receivables |
0.00 | 46.06 | 45.36 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
16.65% | 16.11% | 15.91% |
Intangible Assets out of Total Assets |
0.00 | 0.63 | 0.57 |
Share Based Compensation of Revenue |
0.34% | 0.24% | 0.27% |
Graham Net Nets |
0.00 | 0.00 | (0.25) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
1.97% | 1.97% | 1.97% |
Free Cash Flow Yield |
0.00% | 0.00% | 9.94% |
Revenue per Share |
0.00 | 0.00 | 35.10 |
Operating CF per Share |
0.00 | 0.00 | 2.15 |
Capex per Share |
0.00 | 0.00 | (0.55) |
Free Cash Flow per Share |
0.00 | 0.00 | 1.60 |
Cash per Share |
— | 0.00 | 2.39 |
Shareholders Equity per Share |
0.00 | 0.00 | 23.81 |
Interest Debt per Share |
— | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 23.81 |
Free Cash Flow |
1,410.00 | 1,415.00 | 1,297.00 |
Working Capital |
— | 5,832.00 | 8,189.00 |
Capital Expenditures |
(275.00) | (354.00) | (447.00) |
Net Current Asset Value |
0.00 | (11,548.00) | (8,519.00) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.00 | 0.23 | 0.22 |
Cash ROIC |
0.00% | 4.31% | 3.84% |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.42 |
Accounts Payable Turnover |
0.00 | 0.00 | 22.86 |
Inventory Turnover |
0.00 | 0.00 | 4.53 |
Average Days of Payables |
0.00 | 17.12 | 16.77 |
Days of Inventory on Hand |
0.00 | 87.77 | 83.23 |
Average Receivables |
— | — | 3,376.00 |
Average Payables |
— | — | 915.00 |
Average Inventory |
— | — | 4,612.50 |
Average Assets |
— | 17,989.00 | 37,231.00 |
Average Common Equity |
— | — | 17,722.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026